Shire’s (SHP) “Equal weight” Rating Reaffirmed at Barclays
Other equities research analysts have also issued research reports about the company. Deutsche Bank raised their price objective on Shire from GBX 4,500 ($58.80) to GBX 4,900 ($64.03) and gave the company a buy rating in a research note on Wednesday, August 1st. Liberum Capital restated a hold rating on shares of Shire in a research note on Tuesday, July 10th. Shore Capital restated a hold rating on shares of Shire in a research note on Monday, July 2nd. Berenberg Bank lowered Shire to a hold rating and raised their price objective for the company from GBX 4,500 ($58.80) to GBX 5,000 ($65.33) in a research note on Thursday, September 6th. Finally, UBS Group restated a neutral rating and set a GBX 4,500 ($58.80) price objective on shares of Shire in a research note on Wednesday, August 1st. Eight analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of Buy and a consensus price target of GBX 4,693.14 ($61.32).
SHP stock opened at GBX 4,300.50 ($56.19) on Tuesday. Shire has a 1 year low of GBX 2,940.50 ($38.42) and a 1 year high of GBX 5,021 ($65.61).
Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology.
Featured Article: Investing in Growth Stocks
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.